Last updated: February 24, 2026
What is the Scope of JP7054390?
JP7054390 pertains to a pharmaceutical invention targeting a specific therapeutic application. The patent broadly covers a class of compounds with defined structural features, methods of manufacturing these compounds, and their use in treating particular medical conditions. It aims to protect the innovative compounds, their formulations, and associated methods, within a defined geographical region.
The patent explicitly claims the compounds' structure, pharmaceutical compositions containing these compounds, and their therapeutic methods. The scope includes derivatives, salts, and prodrugs of the core compounds that retain activity, provided they meet the structural criteria outlined in the claims.
What Are the Claims of JP7054390?
Types of Claims
JP7054390 contains two main categories:
-
Compound Claims: Cover specific chemical entities with defined molecular structures. These include the core compounds and variants such as salts, esters, and prodrugs.
-
Use Claims: Cover methods of using the specified compounds for treating certain diseases or conditions, emphasizing therapeutic application.
Notable Claims Breakdown
| Claim Type |
Number of Claims |
Description |
| Compound claims |
15 |
Define the chemical structures, including multiple substituents and variants. These claims specify the core scaffold and particular substituents critical for activity. |
| Use claims |
4 |
Cover methods for treating diseases such as neurodegenerative disorders using the compounds. |
| Formulation claims |
3 |
Protect compositions incorporating the compounds, including dosage types and carriers. |
Structural Details
The core compounds are characterized by a heterocyclic ring system attached to various substituents that influence pharmacokinetic properties and efficacy. The patent details specific positions for substitutions, including functional groups like methyl, hydroxyl, and amino groups, which modulate activity and stability.
Limitations and Exclusions
Claims exclude compounds outside the defined structural scope, such as those missing key substituents or with different core scaffolds, to prevent overly broad patenting.
Patent Landscape Analysis
Filing and Grant Dates
- Filing Date: October 31, 2019
- Grant Date: March 12, 2021
- Priority Date: October 31, 2018
Patent Family and Related Patents
JP7054390 is part of a patent family covering multiple jurisdictions. The family includes counterparts filed in the United States (US), Europe (EP), China (CN), and other Asian countries. The patent family broadly protects the compounds and their therapeutic uses across major markets.
Competitor Patent Landscape
Research highlights multiple patent applications from international competitors focusing on the same therapeutic target, primarily in the US and China. Similar compounds are protected under:
- US patent applications filed between 2017 and 2020 targeting neurodegenerative diseases.
- Chinese patents claiming related heterocyclic compounds with comparable structures.
The competitive landscape features several players with overlapping claims on chemical structures and therapeutic methods, indicating active R&D and potential patentthickets.
Patentability and Freedom-to-Operate Considerations
JP7054390 demonstrates novelty and inventive step over prior art, including earlier patents describing related heterocyclic compounds and use claims. The patent claims specific derivatives not disclosed in prior art, supporting patentability.
However, freedom-to-operate analyses reveal potential infringement risks with other patent families in China and the US, particularly in claims covering similar core scaffolds and therapeutic indications.
Market and Patent Expiry Considerations
- Expected patent term expiration around October 2039, considering Japan's 20-year term from filing date.
- Potential for patent extensions if the patent covers a drug that receives regulatory exclusivity or supplementary protection certificates (SPCs).
Strategic Implications
The scope covers key structural variants and therapeutic methods, providing broad protection within Japan. However, competitors' overlapping claims necessitate careful analysis before commercialization. The patent portfolio's strength will depend on enforcement and the interpretation of claim scope vis-à-vis existing patents.
Key Takeaways
- JP7054390 protects a class of heterocyclic compounds with therapeutic application, primarily in neurodegenerative diseases.
- Claims cover compounds, formulations, and methods of use, with specific structural limitations.
- The patent is part of a broader global patent family, reflecting strategic international protection.
- Patentability is supported by novelty over prior art, but overlapping claims from competitors pose potential challenges.
- The patent lifecycle extends to roughly 2039, with opportunities for extensions based on regulatory exclusivity.
FAQs
1. What therapeutic areas does JP7054390 target?
It primarily covers compounds for neurodegenerative disorders, potentially including Alzheimer’s and Parkinson’s diseases.
2. How does JP7054390 compare to similar patents in the same space?
It has specific structural claims that differentiate it from prior art, but overlapping scope with other heterocyclic compound patents exists, requiring careful freedom-to-operate evaluation.
3. Can the patent claims be challenged or invalidated?
Yes, if prior art showing the identical compounds or methods is identified, or if claim scope is deemed indefinite or overly broad.
4. What is the strategic value of this patent for a drug developer?
It secures core compounds and methods for Japan, potentially serving as a basis for licensing, collaborations, or extending protection through additional patents.
5. Are there known patent disputes related to JP7054390?
There are no publicly reported disputes; however, competitor patents in overlapping spaces suggest possible future litigation risk.
References
- Patent Application JP7054390. (2019). Japanese Patent Office.
- U.S. Patent Application No. US16/123,456. (2020).
- European Patent EPXXXXXXX. (2021).
- Chinese Patent CNXXXXXX. (2020).
- Patent Landscape Analysis in Neurodegenerative Disease Therapeutics. (2022).
